Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Exscientia Plc Stock

Price
Target price
€4.76

€4.76

-1.690%
-0.08
-1.690%
-
 
22.07.24 / Tradegate WKN: A3C4QW / Name: Exscientia Plc / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Exscientia Plc in the next few years
Wizard

Financial data and news for Exscientia Plc

sharewise wants to provide you with the best news and tools for Exscientia Plc, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout


Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all

BusinessWire_EN 
0 18.07.24
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery


Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML)

BusinessWire_EN 
0 10.07.24
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology


Exscientia plc (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology

BusinessWire_EN 
0 06.06.24
Exscientia to Present at Upcoming Investor Conferences in June: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia to Present at Upcoming Investor Conferences in June


Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June:




  • Barclays Digital and Disruptive

BusinessWire_EN 
0 30.05.24
Exscientia Business Update for First Quarter 2024: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Business Update for First Quarter 2024


Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below

BusinessWire_EN 
0 21.05.24
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024


Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference

BusinessWire_EN 
0 14.05.24
Exscientia Business and Financial Update for the Full Year 2023: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Business and Financial Update for the Full Year 2023


Exscientia plc (Nasdaq: EXAI)



Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised

BusinessWire_EN 
0 21.03.24
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024


Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company

BusinessWire_EN 
0 14.03.24
Exscientia to Present at Upcoming Investor Conferences in March: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia to Present at Upcoming Investor Conferences in March


Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March:




  • TD Cowen 44th Annual Health Care Conference.

BusinessWire_EN 
0 28.02.24
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients: https://mms.businesswire.com/media/20211110005488/en/925458/5/5299324_5299274_exscientia-logo.jpg
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients


Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug

BusinessWire_EN 
0 07.02.24